The core mechanism of dry eye disease is inflammation

Eye and Contact Lens

Volumn 40, Issue 4, 2014, Pages 248-256

  Wei, Yi ^a   Asbell, Penny A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; DED; Dry eye disease; Inflammation; Pathogenesis

Indexed keywords

BIOLOGICAL MARKER; ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE;

ADAPTIVE IMMUNITY; ATHEROGENESIS; CELL CULTURE; CHRONICITY; DISEASE SEVERITY; DRY EYE; HUMAN; INFLAMMATION; INNATE IMMUNITY; MEDLINE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TISSUE CULTURE; ANIMAL; COMPLICATION; DISEASE MODEL; DRY EYE SYNDROMES; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; HUMANS; INFLAMMATION; OXIDATIVE STRESS; T-LYMPHOCYTES;

EID: 84905444773     PISSN: 15422321     EISSN: 1542233X     Source Type: Journal    
DOI: 10.1097/ICL.0000000000000042     Document Type: Review

References (86)

1. DEWS. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 75-92.
2. Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130: 90-100.
3. Pflugfelder SC, Stern ME. Immunoregulation on the ocular surface: 2nd Cullen Symposium. Ocul Surf 2009; 7: 67-77.
4. Chen Y, Chauhan SK, Lee HS, et al. Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol 2014; 7: 38-45.
5. Ferrero-Miliani L, Nielsen OH, Andersen PS, et al. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007; 147: 227-235.
6. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
7. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002; 2: 527-535.
8. Epstein SP, Gadaria-Rathod N, Wei Y, et al. HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease. Exp Eye Res 2013; 111: 95-104.
9. Boehm N, Riechardt AI, Wiegand M, et al. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011; 52: 7725-7730.
10. Narayanan S, Corrales RM, Farley W, et al. Interleukin-1 receptor-1- deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye. Cornea 2008; 27: 811-817.
11. Corrales RM, Villarreal A, Farley W, et al. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress. Cornea 2007; 26: 579-584.
12. de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol 2008; 71: 89-95.
13. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009; 147: 198-205.e191.
14. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factoralpha levels in tears of patients with dry eye syndrome. Cornea 2007; 26: 431-437.
15. Enriquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 2010; 16: 862-873.
16. de Paiva CS, Hwang CS, Pitcher JD III, et al. Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren's syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford) 2010; 49: 246-258.
17. Yoon KC, Park CS, You IC, et al. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 2010; 51: 643-650.
18. Gulati A, Sacchetti M, Bonini S, et al. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch Ophthalmol 2006; 124: 710-716.
19. El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci 2009; 50: 3802-3807.
20. Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006; 47: 3293-3302.
21. Acera A, Rocha G, Vecino E, et al. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res 2008; 40: 315-321.
22. Van Der Meid KR, Su SP, Ward KW, et al. Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests. Invest Ophthalmol Vis Sci 2012; 53: 1512-1518.
23. Wei Y, Pinhas A, Liu Y, et al. Isoforms of secretory group two phospholipase a (sPLA2) in mouse ocular surface epithelia and lacrimal glands. Invest Ophthalmol Vis Sci 2012; 53: 2845-2855.
24. Chen D, Wei Y, Li X, et al. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp Eye Res 2009; 88: 880-888.
25. Wei Y, Epstein SP, Fukuoka S, et al. sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model. Invest Ophthalmol Vis Sci 2011; 52: 4780-4788.
26. Nguyen CQ, Yin H, Lee BH, et al. IL17: Potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011; 91: 54-62.
27. Zheng X, de Paiva CS, Li DQ, et al. Desiccating stress promotes Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci 2010; 51: 3083-3091.
28. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009; 2: 243-253.
29. Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol 2009; 2: 375-376.
30. Barabino S, Rolando M, Chen L, et al. Exposure to a dry environment induces strain-specific responses in mice. Exp Eye Res 2007; 84: 973-977.
31. Wei Y, Gadaria-Rathod N, Epstein S, et al. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: Standard operating procedures. Invest Ophthalmol Vis Sci 2013; 54: 8327-8336.
32. Higuchi A, Kawakita T, Tsubota K. IL-6 induction in desiccated corneal epithelium in vitro and in vivo. Mol Vis 2011; 17: 2400-2406.
33. Narayanan S, Manning J, Proske R, et al. Effect of hyperosmolality on betadefensin gene expression by human corneal epithelial cells. Cornea 2006; 25: 1063-1068.
34. Chen DM, Wei Y, Li XH, et al. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp Eye Res 2009; 88: 880-888.
35. Calonge M, Enriquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010; 18: 244-253.
36. Gao J, Schwalb TA, Addeo JV, et al. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: The effect of topical Cyclosporin A therapy. Cornea 1998; 17: 654-663.
37. Gao J, Gelber-Schwalb TA, Addeo JV, et al. Apoptosis in the lacrimal gland and conjunctiva of dry eye dogs. Adv Exp Med Biol 1998; 438: 453-460.
38. Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013; 32: 19-41.
39. Redfern RL, Patel N, Hanlon S, et al. Toll-like receptor expression and activation in mice with experimental dry eye. Invest Ophthalmol Vis Sci 2013; 54: 1554-1563.
40. Stern ME, Schaumburg CS, Siemasko KF, et al. Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease. Invest Ophthalmol Vis Sci 2012; 53: 2062-2075.
41. Pelegrino FSA, Volpe EA, Gandhi NB, et al. Deletion of interferon-gamma delays onset and severity of dacryoadenitis in CD25KO mice. Arthritis Res Ther 2012; 14: R234.
42. Lee CH. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 2012; 35: 3-7.
43. de Paiva CS, Volpe EA, Gandhi NB, et al. Disruption of TGF-beta signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PLoS One 2011; 6: e29017.
44. De Paiva CS, Raince JK, McClellan AJ, et al. Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13. Mucosal Immunol 2011; 4: 397-408.
45. Zheng XF, Bian F, Ma P, et al. Induction of Th17 differentiation by corneal epithelial-derived cytokines. J Cell Physiol 2010; 222: 95-102.
46. Stern ME, Schaumburg CS, Dana R, et al. Autoimmunity at the ocular surface: Pathogenesis and regulation. Mucosal Immunol 2010; 3: 425-442.
47. Bian F, Qi H, Ma P, et al. An immunoprotective privilege of corneal epithelial stem cells against Th17 inflammatory stress by producing glial cell-derived neurotrophic factor. Stem Cells 2010; 28: 2172-2181.
48. Yeh S, de Paiva CS, Hwang CS, et al. Spontaneous T cell mediated keratoconjunctivitis in Aire-deficient mice. Br J Ophthalmol 2009; 93: 1260-1264.
49. Stevenson W, Chauhan SK, Dana R. Dry eye disease an immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130: 90-100.
50. Okanobo A, Chauhan SK, Dastjerdi MH, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012; 154: 63-71.
51. Lee HS, Hattori T, Park EY, et al. Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease. Invest Ophthalmol Vis Sci 2012; 53: 5632-5640.
52. Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 2012; 31: 271-285.
53. Chen Y, Chauhan SK, Saban DR, et al. Interferon-gamma-secreting NK cells promote induction of dry eye disease. J Leukoc Biol 2011; 89: 965-972.
54. Lee HS, Chauhan SK, Okanobo A, et al. Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye. Cornea 2011; 30: 1465-1472.
55. Goyal S, Chauhan SK, El Annan J, et al. Evidence of corneal lymphangiogenesis in dry eye disease: A potential link to adaptive immunity? Arch Ophthalmol 2010; 128: 819-824.
56. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 2009; 182: 1247-1252.
57. Goyal S, Chauhan SK, Zhang Q, et al. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol 2009; 127: 882-887.
58. Wei Y, Li P, Zou J, et al. Secretory group two phospholipase (sPLA2) inhibition decreases corneal superficial punctate keratitis (SPK) in dry eye mice. Paper presented at: ARVO 2013 Annual Meeting; 2013; Seatle, WA. 4326-C0064.
59. Stern ME, Gao JP, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci 2002; 43: 2609-2614.
60. Bikker A, Moret FM, Kruize AA, et al. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Ralpha. Rheumatology (Oxford) 2012; 51: 996-1005.
61. Rojas B, Cuhna R, Zafirakis P, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res 2005; 81: 313-325.
62. Zoukhri D, Kublin CL. Impaired neurotransmission in lacrimal and salivary glands of a murine model of Sjogren's syndrome. Adv Exp Med Biol 2002; 506: 1023-1028.
63. De Saint Jean M, Brignole F, Feldmann G, et al. Interferon-gamma induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40: 2199-2212.
64. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009; 28: 1023-1027.
65. Song XJ, Li DQ, Farley W, et al. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2003; 44: 4223-4229.
66. Luo LH, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004; 45: 4293-4301.
67. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999; 19: 201-211.
68. Epstein SP, Gadaria-Rathod N, Wei Y, et al. HLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface disease. Exp Eye Res 2013; 111: 95-104.
69. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-639.
70. Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147: 206-213.e203.
71. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999; 106: 811-816.
72. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol 2011; 22: 279-282.
73. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul Surf 2010; 8: 18-28.
74. Roncone M, Bartlett H, Eperjesi F. Essential fatty acids for dry eye: A review. Cont Lens Anterior Eye 2010; 33: 49-54; quiz 100.
75. Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008; 126: 219-225.
76. Latkany R. Dry eyes: Etiology and management. Curr Opin Ophthalmol 2008; 19: 287-291.
77. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008; 146: 350-356.
78. Kim TH, Kim JI, Shin MS, et al. Acupuncture for dry eye: A randomised controlled trial protocol. Trials 2009; 10: 112.
79. Wakamatsu TH, Dogru M, Tsubota K. Tearful relations: Oxidative stress, inflammation and eye diseases. Arq Bras Oftalmol 2008; 71: 72-79.
80. Uchino Y, Kawakita T, Miyazawa M, et al. Oxidative stress induced inflammation initiates functional decline of tear production. PLoS One 2012; 7: e45805.
81. Senoo-Matsuda N, Yasuda K, Tsuda M, et al. A defect in the cytochrome b large subunit in complex II causes both superoxide anion overproduction and abnormal energy metabolism in Caenorhabditis elegans. J Biol Chem 2001; 276: 41553-41558.
82. Higuchi A, Inoue H, Kawakita T, et al. Selenium compound protects corneal epithelium against oxidative stress. PLoS One 2012; 7: e45612.
83. Kawashima M, Kawakita T, Inaba T, et al. Dietary lactoferrin alleviates agerelated lacrimal gland dysfunction in mice. PLoS One 2012; 7: e33148.
84. Calonge M, Enriquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010; 18: 190-199.
85. Moschos MM, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses. Cornea 2004; 23: 771-775.
86. Wei Y, Du Z, Chen D, et al. The role of the secretory group IIa phospholipase A2 (sPLA2-IIa) in ocular surface inflammation. JSM Ophthalmol 2013; 1: 1005.